ActivistsInvestorsTrumpPoliticiansSerenityCitriniBurrySemianalysisSwingTradeArbitrageSearch

$DCTH:NASDAQ · Delcath Systems Inc - US

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.

More about this company

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Sector: health

Conviction from: NASDAQ

52-week range: 8.1222.51

2 tracked filer(s) hold this · 1 opened, 1 added, 0 trimmed in 30-SEP-2026

Aggregate 13FScore 68 — mean of 2 scored holder(s) · buyers (new/add) avg 68. Higher = the smart money in this name has the better track record.

Filer13FScoreThis quarterSharesValue% of their book
Steve Cohen / Point7275New buy61,977$989,7730.0%
Paul Tudor Jones / Tudor61Added +1298%168,318$2,688,0380.0%

Beyond 13F — activists, insiders, politicians & research

Activist 13D filings daily digest →

FiledFormActivist% of classConviction
2026-02-10SCHEDULE 13D/ARosalind Advisors, Inc.9.9%Medfiling

Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.